In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogene and its new BG12 drug for multiple sclerosis. However, David favors Gilead over Biogene since Gilead has a larger, more diverse product pipeline. Celgene is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand-new premium report on Celgene. To claim your copy today, simply click here now.
Copyright © 2009 The Motley Fool, LLC. All rights reserved.